A retrospective analysis of the PEAK study in mCRC patients with RAS wild-type primary tumors of left-sided origin showed that patients receiving Vectibix plus FOLFOX6 as first-line treatment achieved 43.4 months median overall survival (OS), an increase of 11.4 months when compared to FOLFOX6 plus bevacizumab.
Mailing a stool-based test directly to people’s homes was the most effective of four strategies for increasing colorectal cancer screening rates, according to a study by UCLA researchers aimed at identifying the best approach to promote CRC screening in adults ages 45 to 49.
